Advice

in the absence of a submission from the holder of the marketing authorisation:

ranibizumab (Lucentis®) is not recommended for use within NHSScotland.

Indication under review: In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice616KB (PDF)

Download

Medicine details

Medicine name:
ranibizumab (Lucentis)
SMC ID:
SMC2274
Indication:

In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
Submission type
Non submission
Status
Not recommended
Date advice published
09 March 2020